Recognition, Staging, and Management of Melanoma

Med Clin North Am. 2021 Jul;105(4):643-661. doi: 10.1016/j.mcna.2021.04.005.

Abstract

Melanoma accounts for approximately 1% of all skin cancers but contributes to almost all skin cancer deaths. The developing picture suggests that melanoma phenotypes are driven by epigenetic mechanisms that reflect a complex interplay between genotype and environment. Furthermore, the growing consensus is that current classification standards, notwithstanding pertinent clinical history and appropriate biopsy, fall short of capturing the vast complexity of the disease. This article summarizes the current understanding of the clinical picture of melanoma, with a focus on the tremendous breakthroughs in molecular classification and therapeutics.

Keywords: Heterogeneity; Management; Melanoma; Staging; Treatment.

Publication types

  • Review

MeSH terms

  • Aged
  • Biopsy
  • Drug Therapy / methods
  • Epigenesis, Genetic / genetics
  • Female
  • GTP Phosphohydrolases / antagonists & inhibitors
  • Genotype
  • Humans
  • Immunotherapy / methods
  • Incidence
  • Male
  • Melanoma / diagnosis*
  • Melanoma / epidemiology
  • Melanoma / genetics*
  • Melanoma / therapy
  • Membrane Proteins / antagonists & inhibitors
  • Mohs Surgery / methods
  • Molecular Targeted Therapy / methods
  • Mutation / genetics
  • Neoplasm Staging / methods*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Skin Neoplasms / ethnology
  • Skin Neoplasms / genetics*
  • Skin Neoplasms / mortality
  • Skin Neoplasms / pathology*
  • United States / epidemiology
  • Young Adult

Substances

  • Membrane Proteins
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • GTP Phosphohydrolases
  • NRAS protein, human